Syncom Formulations (India) Ltd
₹13.44
(-3.86%)
Thu, 19 Feb 2026, 02:09 am
Health Technology
Pharmaceuticals: Major
24.5KSyncom Formulations (India) Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 6.49 | 5.33 | 4.78 | 3.47 | 5.35 | 219.64 | 33.53 | 29.87 | 34.12 | 34.32 | 16.77 | 14.07 | 8.82 | 7.60 | 3.94 | 8.39 | 46.91 | 27.29 | 41.52 | 31.28 |
| Price to book ratio | 1.13 | 0.65 | 0.46 | 0.21 | 0.62 | 0.84 | 1.41 | 1.93 | 4.76 | 3.34 | 1.60 | 1.35 | 0.62 | 0.64 | 0.39 | 1.31 | 4.13 | 2.17 | 3.65 | 4.52 |
| Price to sales ratio | 0.63 | 0.38 | 0.26 | 0.17 | 0.29 | 0.63 | 1.04 | 1.52 | 2.21 | 2 | 0.97 | 0.86 | 0.49 | 0.46 | 0.28 | 1.02 | 4.26 | 2.46 | 4.05 | 3.38 |
| Price to cash flow ratio | 13.09 | 4.49 | 2.93 | 0 | 0 | 0 | 18.16 | 27.93 | 46 | 249.53 | 6.87 | 33.99 | 25.71 | 20.51 | 10.40 | 0 | 61.99 | 74.05 | 0 | 68.51 |
| Enterprise value | 372.75M | 265.56M | 218.8M | 173.25M | 237.35M | 469.43M | 1.19B | 1.68B | 3.22B | 3.34B | 1.74B | 1.59B | 822.6M | 851.11M | 497.8M | 2.33B | 9.44B | 5.6B | 9.92B | 14.61B |
| Enterprise value to EBITDA ratio | 7.53 | 6.07 | 5.95 | 4.44 | 5.29 | 0 | 68.54 | 22.61 | 19.81 | 26.72 | 14.84 | 14.01 | 11.12 | 11.58 | 4.30 | 7.11 | 50.50 | 30.40 | 37.99 | 31.06 |
| Debt to equity ratio | 0.21 | 0.21 | 0.19 | 0.26 | 0.17 | 0.06 | 0.08 | 0.02 | 0.03 | 0.06 | 0.05 | 0.11 | 0.10 | 0.07 | 0.01 | 0.33 | 0.26 | 0.32 | 0.25 | 0.01 |
| Return on equity % | 0 | 12.84 | 9.79 | 6.60 | 9.18 | 0.30 | 4.24 | 6.61 | 10.20 | 9.99 | 9.92 | 9.57 | 7.23 | 8.72 | 10.24 | 17.51 | 9.66 | 8.39 | 9.30 | 15.69 |
Syncom Formulations (India) Ltd Price to Sales Ratio
The Syncom Formulations (India) Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Syncom Formulations (India) Ltd's valuation, profitability, and overall financial performance. Tracking the Syncom Formulations (India) Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Syncom Formulations (India) Ltd (NSE: SYNCOMF, BSE: 524470) is currently trading at ₹13.44, with a market capitalization of ₹13.18B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Syncom Formulations (India) Ltd Price to Sales Ratio is essential for fundamental analysis.
Syncom Formulations (India) Ltd Price to Sales Ratio Current Value
The current Syncom Formulations (India) Ltd Price to Sales Ratio stands at 3.38.
The Syncom Formulations (India) Ltd Price to Sales Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Syncom Formulations (India) Ltd Price to Sales Ratio Historical Trend
The Syncom Formulations (India) Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 3.38
- 2023: 4.05
- 2022: 2.46
- 2021: 4.26
- 2020: 1.02
The decline in Syncom Formulations (India) Ltd Price to Sales Ratio indicates improving financial efficiency or better earnings growth.
What Syncom Formulations (India) Ltd Price to Sales Ratio Indicates for Investors
The Syncom Formulations (India) Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Syncom Formulations (India) Ltd Price to Sales Ratio Analysis Summary
The Syncom Formulations (India) Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Syncom Formulations (India) Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Syncom Formulations (India) Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800